Low Molecular Weight Thiocarbamates as Inhibitors of Elastase, Uses and Method of Synthesis

To see this abstract, please download this patent

Multimodal Explainable Artificial Intelligence: A Comprehensive Review of Methodological Advances and Future Research Directions

The current study focuses on systematically analyzing the recent advances in the field of Multimodal eXplainable Artificial Intelligence (MXAI). In particular, the relevant primary prediction tasks and publicly available datasets are initially described. Subsequently, a structured presentation of the MXAI methods of the literature is provided, taking into account the following criteria: a) The number of the involved modalities, b) The stage at which explanations are produced, and c) The type of the adopted methodology (i.e. mathematical formalism). Then, the metrics used for MXAI evaluation are discussed. Finally, a comprehensive analysis of current challenges and future research directions is provided.Comment: 26 pages, 11 figure

Multimodal Explainable Artificial Intelligence: A Comprehensive Review of Methodological Advances and Future Research Directions

Despite the fact that Artificial Intelligence (AI) has boosted the achievement of remarkable results across numerous data analysis tasks, however, this is typically accompanied by a significant shortcoming in the exhibited transparency and trustworthiness of the developed systems. In order to address the latter challenge, the so-called eXplainable AI (XAI) research field has emerged, which aims, among others, at estimating meaningful explanations regarding the employed model’s reasoning process. The current study focuses on systematically analyzing the recent advances in the area of Multimodal XAI (MXAI), which comprises methods that involve multiple modalities in the primary prediction and explanation tasks. In particular, the relevant AI-boosted prediction tasks and publicly available datasets used for learning/evaluating explanations in multimodal scenarios are initially described. Subsequently, a systematic and comprehensive analysis of the MXAI methods of the literature is provided, taking into account the following key criteria: a) The number of the involved modalities (in the employed AI module), b) The processing stage at which explanations are generated, and c) The type of the adopted methodology (i.e. the actual mechanism and mathematical formalization) for producing explanations. Then, a thorough analysis of the metrics used for MXAI methods’ evaluation is performed. Finally, an extensive discussion regarding the current challenges and future research directions is provided

Clinical Aspects in Subacute Thyroiditis:A Real-Life Study on 226 Cases in Greece Amid the COVID-19 Pandemic

PURPOSE: This study aimed to evaluate various therapeutic approaches, identify potential predictive factors for the recurrence and development of hypothyroidism, and examine specific clinical and laboratory characteristics of patients with subacute thyroiditis (SAT) due to SARS-CoV-2 infection.METHODS: We retrospectively analyzed the medical records of 226 patients with confirmed SAT diagnosed from January 2020 to November 2022.RESULTS: The mean age was 48.01 ± 0.75 years, and the F/M ratio was 2.3/1. At the end of the follow-up period, 69 patients (32.1%) had developed hypothyroidism. Treatment duration was significantly shorter with nonsteroidal anti-inflammatory drugs (NSAIDs) (17.40 ± 2.56 days), while time-to-symptom relief was shorter with glucocorticoids (CGs). Recurrence was observed only in those treated with corticosteroid preparations (14.1%). C-reactive protein levels at treatment discontinuation were higher in patients who experienced SAT recurrence, while the coexistence of Hashimoto's thyroiditis was a significant predictive factor for the development of hypothyroidism. The TSH value at the time of treatment withdrawal &gt;4.12 μIU/mL showed optimal sensitivity and specificity for the prediction of permanent hypothyroidism. Regarding COVID-19, 34 patients (15%) experienced related SAT, with similar clinical manifestations of the disease but a higher BMI and shorter time-to-symptom relief.CONCLUSION: In conclusion, GCs administration alleviated acute symptoms earlier during the onset of SAT, whereas NSAIDs had a shorter treatment duration, and both regimens could not prevent the development of delayed hypothyroidism. The clinical characteristics of SAT due to COVID-19 infections were similar to those of typical SAT disease.</p